To delineate the relative roles of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas ligand in lymphocyte biology and lymphoproliferative disease, we generated mice defective in both molecules. B6.GT mice develop severe polyclonal lymphoproliferative disease because of accumulating CD3 ؉ CD4 ؊ CD8 ؊ B220 ؉ T cells, CD4 ؉ and CD8 ؉ T cells, and follicular B cells, and mice die prematurely from extreme lymphocytosis, thrombocytopenia, and hemorrhage. IntroductionApoptotic cell death is mediated primarily by 2 distinct pathways: the intrinsic mitochondrial-sensed, Bcl2-family regulated pathway and the extrinsic death-ligand/receptor pathway. Members of the tumor necrosis factor (TNF) family of death-inducing ligands, such as Fas ligand (FasL), TNF, and TNF-related apoptosis-inducing ligand (TRAIL), compose the extrinsic pathway, and these molecules bind to specific receptors that contain a "death-domain" signature in their cytoplasmic region. For FasL and TRAIL, ligand binding results in recruitment of Fas-associated death domain adaptor protein to the receptor's death domain enabling subsequent recruitment and activation of procaspase-8 and/or procaspase-10. Apical caspases then act on downstream effector caspases that leads to degradation of the inhibitor of the caspase-activated DNase, with cleavage of dsDNA causing apoptotic cell death. 1 To date, however, the specific roles and redundancies of the multiple death TNF-family death ligands and receptors are unclear.Despite the conservation in intracellular death receptor signaling, the biologic functions of TNF/TNFR molecules in vivo appear to be divergent. TNF-␣ is an important mediator of inflammation 2 and a key cause of apoptosis of virus-infected cells, 3 and FasL/Fas plays a critical role in the elimination of self-reactive lymphocytes and in regulating T cell homeostasis. 4 In contrast, the physiologic role of TRAIL in vivo is still emerging. TRAIL specifically kills transformed 5 and virally infected cells 6 and controls tumor growth and metastasis contributing to tumor surveillance. [7][8][9][10] The inert properties of LZ-TRAIL on normal cells 5,11 has led to Apo2L/ TRAIL protein and agonistic receptor-specific antibodies being trialed for the treatment of human cancers. However, it is debatable whether TRAIL's tumoricidal activity provides sufficient evolutionary pressure for its existence as the fourth death ligand/receptor system in humans. That cancer most frequently occurs in persons after child-bearing age and that TNF-␣ and FasL also have tumorigenic properties 12,13 suggest that TRAIL/TRAIL-Rs mediates biologic functions that remain to be defined. Curiously, the study of TRAIL Ϫ/Ϫ mice revealed little about the roles of TRAIL in vivo as these mice are essentially physiologically normal. 7 It is now apparent that, because most cells that express TRAIL also express FasL 14 and because TRAIL and FasL initiate a death-signaling pathway that is almost identical, 15 attempts to define the physiologic role of TRAIL/TRAIL-Rs in vi...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.